ITM Isotope Technologies Munich SE and Alpha-9 Oncology have signed a global clinical supply agreement to support the development of Alpha-9's radiopharmaceutical therapy pipeline candidates for cancer treatment.
Through the agreement, ITM will supply its medical radioisotope, non-carrier-added lutetium-177 (Lu-177) for Alpha-9's Lutetium-based candidates.
ITM holds a U.S. Drug Master File with the U.S. Food and Drug Administration for non-carrier-added Lu-177 and has marketing authorization in the EU (brand name EndolucinBeta).
